Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cannabis Stock Movers For April 18, 2023

GAINERS: Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 14.72% at $12.00 MariMed (OTC:MRMD) shares closed up 11.51% at $0.43…
byBenzinga Insights
April 18, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

GAINERS:

  • Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 14.72% at $12.00
  • MariMed (OTC:MRMD) shares closed up 11.51% at $0.43
  • BioHarvest Sciences (OTC:CNVCF) shares closed up 5.47% at $0.16
  • 22nd Century Group (NASDAQ:XXII) shares closed up 4.34% at $0.71
  • Cronos Group (NASDAQ:CRON) shares closed up 4.08% at $2.04
  • Charlottes Web Holdings (OTC:CWBHF) shares closed up 4.02% at $0.36

LOSERS:

  • 4Front Ventures (OTC:FFNTF) shares closed down 9.60% at $0.16
  • Innovative Ind Props (NYSE:IIPR) shares closed down 4.25% at $69.27
  • Village Farms Intl (NASDAQ:VFF) shares closed down 3.98% at $0.81
  • Cara Therapeutics (NASDAQ:CARA) shares closed down 3.84% at $4.26
  • GrowGeneration (NASDAQ:GRWG) shares closed down 3.58% at $3.23
  • Canopy Gwth (NASDAQ:CGC) shares closed down 3.38% at $1.43
  • OrganiGram Holdings (NASDAQ:OGI) shares closed down 3.38% at $0.54
  • SNDL (NASDAQ:SNDL) shares closed down 3.18% at $1.52

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Australian Market Opens Up To Clever Leaves With GMP Certification For Cannabis Manufacturing

By Jelena Martinovic
January 3, 11:04 AM
Colombian medical cannabis company Clever Leaves has been granted Good Manufacturing Practice (GMP) certification by the Australian Therapeutic Goods Administration (TGA). The certification allows Clever Leaves to manufacture cannabis products for patients in Australia. GMP certification ensures the quality and safety of pharmaceutical products by safeguarding against issues such as contamination, compound variations, product mix-ups, and incorrect labelling. The certification is a prerequisite for manufacturing and commercialising cannabis products in the Australian market. According to TGA data, 325,000 new Australian patients commenced cannabis treatment in the first half of 2023, with 320,000 new patients in 2022 and 150,000 in 2021. Clever Leaves already distributes finished cannabis products in Australia through its partners.

CLVR